Natco Pharma has secured in-principle approval from BSE and NSE for its planned rights issue. While this regulatory nod marks a major step forward, the company has yet to announce the record date, issue price, or entitlement ratio. Shareholders should monitor upcoming filings for the final terms of the offer.
Natco Pharma Cleared for Rights Issue
Exchange approval received September 21, 2026.
Rights issue launch moves to next phase after BSE and NSE in-principle nod.
Reader Takeaway: Regulatory hurdle cleared for capital raise, but key pricing and ratio details remain pending disclosure.
What just happened
Natco Pharma has officially received in-principle approval from both the BSE and the National Stock Exchange of India (NSE) to proceed with its proposed rights issue of fully paid-up equity shares. This approval, granted on September 21, 2026, serves as the primary regulatory green light required to move forward with the capital-raising process.
Why this matters
A rights issue allows existing shareholders to purchase additional shares at a discounted price, usually aimed at funding expansion or debt repayment. For investors, this represents a potential dilution of current holdings balanced by the opportunity to increase their stake at a specific price point. With the exchanges on board, the company is now set to finalize the specifics of the offer.
What changes now
Following this approval, the company must now prepare and file the draft letter of offer and final offering documents. Shareholders should be aware that the most critical details—including the record date, the issue price, and the entitlement ratio—are currently undisclosed. These figures will determine the actual cost and benefit to existing investors.
What to track next
Investors should keep a close watch on future BSE and NSE filings and the company’s investor relations portal. The announcement of the record date will be the most significant upcoming event, as it defines which investors are eligible to participate in the rights issue.